Crossmark

Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology

Crossref DOI link: https://doi.org/10.1007/s40520-026-03391-7

Published Online: 2026-04-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Semeraro, Angelo

Chialà, Angela

Carafa, Andrea

Fanizzi, Rosalinda

Di Tano, Elisabetta

Palmisano, Maria

Santoro, Carmela

Dibenedetto, Federica

Napoli, Nicola
License Information

Text and Data Mining valid from 2026-04-11

Version of Record valid from 2026-05-22
More Information

Article History

Received: 13 March 2026

Accepted: 25 March 2026

First Online: 11 April 2026

Declarations

:

: The authors declare no competing interests.

: This study was approved by the Ethics Review Board of the participating hospital, and it was conducted in accordance with the ethical standards of the Declaration of Helsinki (1964).

: Informed consent for participation and publication has been obtained from all the participants included in the study.

Document is current

Any future updates will be listed below